Skye Bioscience (SKYE)

• Market cap: $90.4M
• 1 day: -4.79%
• 5 days: -2.93%
• 1 month: 10.37%
• 3 months: -28.54%
• 6 months: -45.72%
• Year to date: 4.56%
• 1 year: -76.52%
• 5 years: -76.52%
• 10 years: -76.52%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Employees: 11

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

190% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 10

8% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 12

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

1% less funds holding

Funds holding: 74 [Q3] → 73 (-1) [Q4]

1.76% less ownership

Funds ownership: 84.84% [Q3] → 83.09% (-1.76%) [Q4]

29% less capital invested

Capital invested by funds: $101M [Q3] → $71.3M (-$29.3M) [Q4]